Raymond James Analysts Boost Earnings Estimates for TSE:MDP

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities researchers at Raymond James upped their FY2025 earnings per share (EPS) estimates for shares of Medexus Pharmaceuticals in a research report issued to clients and investors on Monday, February 3rd. Raymond James analyst M. Freeman now forecasts that the company will post earnings of $0.07 per share for the year, up from their previous forecast of $0.03. Raymond James has a “Strong-Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at $0.07 EPS, FY2026 earnings at ($0.51) EPS, FY2028 earnings at $2.10 EPS and FY2029 earnings at $3.05 EPS.

Several other research firms have also issued reports on MDP. Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 17th. Leede Financial upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, January 22nd. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Ventum Financial lifted their price objective on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a “buy” rating in a report on Thursday, January 30th. Finally, Stifel Nicolaus upped their price target on Medexus Pharmaceuticals from C$4.50 to C$6.00 in a research report on Thursday, January 30th. Two investment analysts have rated the stock with a buy rating and five have issued a strong buy rating to the company. According to data from MarketBeat, Medexus Pharmaceuticals presently has an average rating of “Strong Buy” and a consensus target price of C$6.13.

Medexus Pharmaceuticals Stock Down 2.1 %

MDP stock opened at C$3.79 on Thursday. Medexus Pharmaceuticals has a 52 week low of C$1.47 and a 52 week high of C$5.56. The business has a 50-day simple moving average of C$3.52 and a 200 day simple moving average of C$2.82. The company has a market cap of C$92.97 million, a PE ratio of 75.80 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.